Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

被引：0
|
作者：
Daniel H. Deck
Jennifer M. Jordan
Thomas L. Holland
Weihong Fan
Matthew A. Wikler
Katherine A. Sulham
G. Ralph Corey
机构：
[1] The Medicines Company,
[2] Duke University Hospital,undefined
来源：
Infectious Diseases and Therapy | 2016年 / 5卷 / 3期
关键词：
D O I：
10.1007/s40121-016-0127-9
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：363 / 365
页数：2
相关论文
共 50 条
  • [41] The Potential Utility of Single-Dose Long-Acting Intravenous Antibiotics for Acute Bacterial Skin and Skin-Structure Infections in the Emergency Department
    Weant, Kyle A.
    Gregory, Haili
    ADVANCED EMERGENCY NURSING JOURNAL, 2023, 45 (03) : 177 - 186
  • [42] Novel developments in the treatment of acute bacterial skin and skin structure infections
    Jaffa, Rupal K.
    Pillinger, Kelly E.
    Roshdy, Danya
    Isip, Jacqueline A.
    Pasquale, Timothy R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (12) : 1493 - 1502
  • [43] The safety of treatment options for acute bacterial skin and skin structure infections
    Bassetti, Matteo
    Peghin, Maddalena
    Castaldo, Nadia
    Giacobbe, Daniele Roberto
    EXPERT OPINION ON DRUG SAFETY, 2019, 18 (08) : 635 - 650
  • [44] Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections
    Beresford, Eric
    Biek, Donald
    Jandourek, Alena
    Mawal, Yogesh
    Riccobene, Todd
    Friedland, H. David
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (02) : 123 - 135
  • [45] TEDIZOLID PHOSPHATE FOR THE TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
    Gras, J.
    DRUGS OF TODAY, 2014, 50 (11) : 729 - 737
  • [46] BUDGET IMPACT ANALYSIS OF ORITAVANCIN FOR THE TREATMENT OF MODERATE TO SEVERE ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) FROM A HOSPITAL PERSPECTIVE
    Garg, M.
    Venugopalan, V.
    Premraj, S.
    Park, H.
    VALUE IN HEALTH, 2018, 21 : S151 - S151
  • [47] Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital
    Saddler, Kimberly
    Zhang, Jason
    Sul, Jennifer
    Patel, Pruthvi
    Castro-Lainez, Miriams
    Stevens, Mark L.
    Kosler, Sheryl
    Lowery, Emily
    Sierra-Hoffman, Miguel
    PLOS ONE, 2021, 16 (03):
  • [48] Safety, Tolerability, and Efficacy of GSK1322322 in the Treatment of Acute Bacterial Skin and Skin Structure Infections
    Corey, Ralph
    Naderer, Odin J.
    O'Riordan, William D.
    Dumont, Etienne
    Jones, Lori S.
    Kurtinecz, Milena
    Zhu, John Z.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) : 6518 - 6527
  • [49] The optimal duration of treatment for skin and soft tissue infections and acute bacterial skin and skin structure infections
    Corcione, Silvia
    De Rosa, Francesco Giuseppe
    CURRENT OPINION IN INFECTIOUS DISEASES, 2018, 31 (02) : 155 - 162
  • [50] Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections
    Ferrandez, Olivia
    Urbina, Olatz
    Grau, Santiago
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 65 - 82
12345